Abbott Wins Preliminary Injunction Against Andrx, Ranbaxy for Biaxin XL

Drug Industry Daily
KEYWORDS courts
A A

In what one analyst called a “significant negative” for beleaguered Andrx, a federal court has granted Abbott Laboratories a preliminary injunction blocking Andrx and Ranbaxy Laboratories from marketing generic versions of Biaxin XL.

To View This Article:

Login

Subscribe To Drug Industry Daily